Actively Recruiting
Open-label Dose-escalation Study Evaluating Safety of HB1011 Stem Cell Therapy Injected During Coronary Artery Bypass Surgery in Ischemic Cardiomyopathy Patients
Led by HieraBio Inc. · Updated on 2026-10-06
12
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Ischemic cardiomyopathy is a condition where the heart muscle is weakened due to blocked arteries that reduce blood flow. Current treatments can manage symptoms but do not repair the damage. Researchers are evaluating HB1011, an allogeneic myocardium-derived mesenchymal stem cell therapy, to assess its safety and tolerability in patients undergoing coronary artery bypass grafting CABG surgery. Participants will receive HB1011 injections directly into the damaged heart muscle during the CABG procedure. The study uses a dose-escalation design with two groups receiving either a low dose 0.5 x 107 cells or a high dose 1.0 x 107 cells via multiple intramyocardial injections. Safety will be closely monitored before advancing to higher doses. The study lasts about 12 months per participant. Before surgery, screening includes physical exams, medical reviews, blood tests, ECG, echocardiogram, and cardiac MRI. After surgery and treatment, participants will have outpatient visits at 1, 3, 6, 9, and 12 months for safety checks and heart function assessments using echocardiograms and MRIs. Researchers will measure adverse events, dose-limiting toxicities, and changes in heart function and structure.
CONDITIONS
Brief Title
A Phase I Study of Allogeneic Myocardium-Derived Mesenchymal Stem Cells (HB1011) in Patients With Ischemic Cardiomyopathy
Research Team
H
HeeJung Kim, CTO
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here